<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9806">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756105</url>
  </required_header>
  <id_info>
    <org_study_id>4965</org_study_id>
    <nct_id>NCT01756105</nct_id>
  </id_info>
  <brief_title>Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women</brief_title>
  <official_title>Gestational Diabetes in Non Obese Women and Metformine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes (GD) is defined by a hyperglycemia discovered during pregnancy, leading
      to fetal and maternal complications which may be prevented by reaching very strict glycaemia
      targets. Prevalence depends on patient's ethnic group and is about 6 to 14%. This prevalence
      is increasing due to increased GD risk factors (obesity, pregnancy over 35) and also because
      criteria of screening have been strengthened after the results of last studies. Usual
      treatment is diet and in case of failure insulin therapy with multiple injections which may
      lead to hypoglycemia and weight gain and is very difficult to manage for patients. Some
      studies have shown the comparable effect of metformin and insulin in about 50% of GD obese
      patients. The aim of our study is to evaluate efficacy of metformin, outcomes in mother and
      fetus and baby of metformin. In case of metformin failure, insulin will be added in order to
      obtain glycaemia in desired goals.Oxidative stress will be assessed in mother blood, baby
      umbilical cord blood, baby umbilical cord and placenta in 90 women and the oxidative stress
      compared between insulin and metformin alone treated patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of metformin in treatment of gestational diabetes based on capillary glycaemia with an objective of less than 6 measures out of range</measure>
    <time_frame>After diagnosis of gestational diabetes and until 3 months after delivery; screening made between 22th and 28th week of gestation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Metformin</condition>
  <condition>Treatment</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>treatment by Metformin plus insulin if needed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment by insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin therapy:If post meal (2 hours after meal) glycaemia is &gt; to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is &lt; 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is &gt; 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is &lt; 80 kg - 6U if weight is &gt; 80 kgIf fasting glycaemia stay over 95 mg/dl increase  NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of</description>
    <arm_group_label>treatment by Metformin plus insulin if needed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapid acting analog insulin    Intermediate acting NPH Insulin</intervention_name>
    <description>Insulin therapy:If post meal (2 hours after meal) glycaemia is &gt; to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is &lt; 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is &gt; 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is &lt; 80 kg - 6U if weight is &gt; 80 kgIf fasting glycaemia stay over 95 mg/dl increase  NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.</description>
    <arm_group_label>treatment by Metformin plus insulin if needed</arm_group_label>
    <arm_group_label>treatment by insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women.

          -  Age more than 18 and less than 40 years.

          -  Unique spontaneous pregnancy.-BMI less than 30kg/m2 before pregnancy.

          -  24 to 30 weeks of amenorrhea or 22 to 28 weeks of gestation.

          -  Gestational diabetes.

          -  Social Security affiliated subject.- Patient able to understand and signed informed
             consent.

        Exclusion Criteria:

          -  Contraindications to metformin.

          -  Metformin treatment prior to protocol inclusion.

          -  Multiple pregnancies.

          -  Diabetes diagnosed prior to pregnancy.

          -  High blood pressure prior to pregnancy.

          -  Pregnancy hepatic complication

          -  High blood pressure prior to study inclusion.

          -  Pre or eclampsia.- Premature membranes rupture.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Jeandidier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Jeandidier, MD</last_name>
    <phone>03 88 11 66 03</phone>
    <phone_ext>0033</phone_ext>
    <email>nathalie.jeandidier@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel GERSON, MD</last_name>
      <phone>O3 89 12 42 24</phone>
      <phone_ext>0033</phone_ext>
      <email>michel.gerson@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>michel Gerson, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon,</name>
      <address>
        <city>Dijon</city>
        <zip>21030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine RUDONI, MD</last_name>
      <phone>03.80.29.34.53</phone>
      <phone_ext>0033</phone_ext>
      <email>Sabine.rudoni@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Sabine Rudoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine MILLOT, MD</last_name>
      <phone>03.89.64.61.66</phone>
      <phone_ext>0033</phone_ext>
      <email>millots@ch-mulhouse.fr</email>
    </contact>
    <investigator>
      <last_name>Sabine Millot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maud FRANCOIS, MD</last_name>
      <phone>03 26 78 71 54</phone>
      <phone_ext>0033</phone_ext>
      <email>mfrancois@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Maud François, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Jeandidier, MD</last_name>
      <phone>03 88 11 66 03</phone>
      <phone_ext>0033</phone_ext>
      <email>nathalie.jeandidier@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Jeandidier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 19, 2012</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, NPH</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
